RVMD
Revolution Medicines, Inc.
NASDAQ · Healthcare · Biotechnology · US
$210.02
−0.40%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−24.6x
Market Cap
$45.01B
MomentumView details →
1D Return
−0.40%
YTD Return
+162.09%
RSI (14)
54.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−24.6x
Market Cap
$45.01B
RSI (14)
54.3
MomentumView details →
1D Return
−0.40%
YTD Return
+162.09%
SummaryUpdated Jun 1, 2026
Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company founded in 2014 and headquartered in Redwood City, California. The company went public in February 2020 and focuses specifically on developing novel therapies to treat RAS-addicted cancers. RAS proteins are among the most frequently mutated oncogenes in human cancers, found in approximately 30% of all cancers and up to 95% in certain cancer types like pancreatic cancer. Revolution Medicines has built a comprehensive pipeline of RAS pathway inhibitors and is currently advancing multiple drug candidates through clinical trials, with its lead program entering Phase 3 pivotal trials.
Similar companies
Latest newsMore news →
Revolution Medicines announced that The New England Journal of Medicine published Phase 1/2 clinical data on its drug RASONQUE (daraxonrasib) for metastatic non-small cell lung cancer.2d agoRevolution Medicines, Inc. signed four lease agreements for buildings at 1600, 1700, 1800 and 1900 Seaport Boulevard in Redwood City, California, with staggered commencements from September 26, 2027 to September 1, 2028 and initial terms ending September 2042, subject to Phase II Closing by the landlords' acquisition of the properties.4d agoRevolution Medicines' drug daraxonrasib (brand name Rasonque) was approved by the FDA this week for treating pancreatic cancer with a key mutation.7d ago